Sancak Y, Thoreen CC, Peterson TR, et al. PRAS40 is an insulin-regulated inhibitor of the mTORC1 protein kinase. Mol Cell. 2007;25(6):903-15. doi:10.1016/j.molcel.2007.03.003
Kalaitzidis D, Sykes SM, Wang Z, et al. mTOR complex 1 plays critical roles in hematopoiesis and Pten-loss-evoked leukemogenesis. Cell Stem Cell. 2012;11(3):429-39. doi:10.1016/j.stem.2012.06.009
Hästbacka J, Kerrebrock A, Mokkala K, et al. Identification of the Finnish founder mutation for diastrophic dysplasia (DTD). Eur J Hum Genet. 1999;7(6):664-70. doi:10.1038/sj.ejhg.5200361
Boulbes D, Chen CH, Shaikenov T, et al. Rictor phosphorylation on the Thr-1135 site does not require mammalian target of rapamycin complex 2. Mol Cancer Res. 2010;8(6):896-906. doi:10.1158/1541-7786.MCR-09-0409
Raimondo A, Rees MG, Gloyn AL. Glucokinase regulatory protein: complexity at the crossroads of triglyceride and glucose metabolism. Curr Opin Lipidol. 2015;26(2):88-95. doi:10.1097/MOL.0000000000000155
Klockars T, Holmberg V, Savukoski M, Lander ES, Peltonen L. Transcript identification on the CLN5 region on chromosome 13q22. Hum Genet. 1999;105(1-2):51-6.
Whiteaker JR, Zhao L, Abbatiello SE, et al. Evaluation of large scale quantitative proteomic assay development using peptide affinity-based mass spectrometry. Mol Cell Proteomics. 2011;10(4):M110.005645. doi:10.1074/mcp.M110.005645
Guda S, Brendel C, Renella R, et al. miRNA-embedded shRNAs for Lineage-specific BCL11A Knockdown and Hemoglobin F Induction. Mol Ther. 2015;23(9):1465-74. doi:10.1038/mt.2015.113
Van Allen EM, Pomerantz M. Moving toward personalized medicine in castration-resistant prostate cancer. Urol Clin North Am. 2012;39(4):483-90. doi:10.1016/j.ucl.2012.07.005